Looking back on three years of operations in Canada and nine months of approval of Ocaliva® for the rare non-viral liver disease PBC, Brian Canestraro, general manager of Intercept, is proud of how far the Canadian affiliate has come. He is confident that the company has established a solid foundation to build upon by focusing on core values, market access capability and keeping a continuous focus on the needs of patients.
How have the beginnings of Intercept in Canada unfolded?
"From the very beginning, it was important to make sure that every decision was made through the lens of what is right for patients."
